Invention Grant
US09360481B2 Predictive biomarker for cancer treatment with ADCC-enhanced antibodies
有权
用ADCC增强抗体进行癌症治疗的预测性生物标志物
- Patent Title: Predictive biomarker for cancer treatment with ADCC-enhanced antibodies
- Patent Title (中): 用ADCC增强抗体进行癌症治疗的预测性生物标志物
-
Application No.: US14159895Application Date: 2014-01-21
-
Publication No.: US09360481B2Publication Date: 2016-06-07
- Inventor: Lilla Di Scala , Stefan Evers , Christian Gerdes , Christoph Mancao , Alexandre Passioukov , Pablo Umana
- Applicant: Roche Glycart AG
- Applicant Address: CH Schlieren
- Assignee: Roche Glycart AG
- Current Assignee: Roche Glycart AG
- Current Assignee Address: CH Schlieren
- Priority: EP13152293 20130123
- Main IPC: A61K39/395
- IPC: A61K39/395 ; G01N33/53 ; G01N33/574 ; C07K16/30
Abstract:
The present invention is directed to methods for identifying which patients diagnosed with cancer will most benefit from treatment with an anti-cancer therapy comprising an ADCC-enhanced antibody.
Public/Granted literature
- US20140227256A1 Predictive biomarker for cancer treatment with ADCC-enhanced antibodies Public/Granted day:2014-08-14
Information query
